Search results for " patient selection"

showing 5 items of 15 documents

Eligibility for treatment with omalizumab in Italy and Germany.

2013

Summary Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Europe, patients must fulfil a number of additional criteria to become eligible for omalizumab therapy, creating a challenge for epidemiology studies to quantify the potential patient pool. Thus, and in the absence of robust data, the number of omalizumab-eligible patients has remained unclear. To assess eligible patient numbers, a chart-audit design approach was employed to measure epidemiology variables based on patient-level data. 770 patient charts were reviewed in designated towns in Germany and Italy, in collaboration with >200 primary care physicians (PCPs) and respiratory specialists (R…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricsReferralEpidemiologySevere asthmaAllergic asthmaEligibility DeterminationOmalizumabPrimary careOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness IndexAntibodiesSampling StudiesDose-Response RelationshipProduct LabelGermanyEpidemiologyMonoclonalmedicinePrevalenceHumansNational levelAnti-Asthmatic AgentsHumanizedAnti-immunoglobulin EEligibilityDose-Response Relationship Drugbusiness.industryPatient SelectionAllergic asthmaImmunoglobulin EAsthmaAntibodies Anti-IdiotypicAnti-IdiotypicTreatment OutcomeItalyQuality of LifeBiological MarkersDrugbusinessBiomarkersmedicine.drugAllergic asthma; Anti-immunoglobulin E; Eligibility; Epidemiology; Anti-Asthmatic Agents; Antibodies Anti-Idiotypic; Antibodies Monoclonal Humanized; Asthma; Biological Markers; Dose-Response Relationship Drug; Eligibility Determination; Germany; Humans; Immunoglobulin E; Italy; Patient Selection; Prevalence; Quality of Life; Sampling Studies; Severity of Illness Index; Treatment OutcomeRespiratory medicine
researchProduct

Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies

2015

Patients affected with intra-thoracic recurrences of primary or secondary lung malignancies after a first course of definitive radiotherapy have limited therapeutic options, and they are often treated with a palliative intent. Re-irradiation with stereotactic ablative radiotherapy (SABR) represents an appealing approach, due to the optimized dose distribution that allows for high-dose delivery with better sparing of organs at risk. This strategy has the goal of long-term control and even cure. Aim of this review is to report and discuss published data on re-irradiation with SABR in terms of efficacy and toxicity. Results indicate that thoracic re-irradiation may offer satisfactory disease c…

ThoraxRe-Irradiationmedicine.medical_specialtyLung NeoplasmsStereotactic body radiotherapymedicine.medical_treatmentLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapseLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapse; Humans; Lung Neoplasms; Patient Selection; Radiotherapy Dosage; Thorax; Radiosurgery; Oncology; Radiology Nuclear Medicine and ImagingSABR volatility modelRadiosurgeryRadiosurgeryNuclear Medicine and ImagingAblative casemedicineHumansRadiology Nuclear Medicine and imagingLung cancerThoracic relapsebusiness.industryPatient SelectionRetrospective cohort studyRadiotherapy DosageGeneral MedicineThoraxmedicine.diseaseRadiation therapyOncologyRe-irradiationRadiologyStereotactic ablative radiotherapyLung cancerbusinessRadiology
researchProduct

Introduction to coronary imaging with 64-slice computed tomography

2005

The aim of this article is to illustrate the main technical improvements in the last generation of 64-row CT scanners and the possible applications in coronary angiography. In particular, we describe the new physical components (X-ray tube-detectors system) and the general scan and reconstruction parameters. We then define the scan protocols for coronary angiography with the new generation of 64-row CT scanners to enable radiologists to perform a CT study on the basis of the diagnostic possibilities.

Time FactorsImaging Sensitivity and Specificity Stents Time Factors TomographyContrast MediaSensitivity and Specificity64-row CTElectrocardiographyHeart RateSpiral Computed TomographyImage Processing Computer-AssistedHumanstechnical improvementsCoronary Artery BypassPhantoms ImagingPatient SelectionAlgorithms Artifacts Contrast Media Coronary Angiography/instrumentation/*methods Coronary Artery Bypass Coronary Stenosis/*radiography Electrocardiography Heart Rate Humans Image Processing; Computer-Assisted Patient Selection Phantoms; Imaging Sensitivity and Specificity Stents Time Factors Tomography; Spiral Computed Tomography; X-Ray Computed/instrumentation/*methodsCoronary StenosisComputer-Assisted Patient Selection PhantomsX-Ray Computed/instrumentation/*methodstechnical improvements; 64-row CT; coronary angiographyComputer-Assisted Patient Selection PhantomStentsAlgorithms Artifacts Contrast Media Coronary Angiography/instrumentation/*methods Coronary Artery Bypass Coronary Stenosis/*radiography Electrocardiography Heart Rate Humans Image Processingcoronary angiographyArtifactsTomography X-Ray ComputedTomography Spiral ComputedAlgorithms
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct